Leerink Partnrs Comments on Zentalis Pharmaceuticals, Inc.’s Q2 2024 Earnings (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Leerink Partnrs dropped their Q2 2024 earnings estimates for Zentalis Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 7th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($0.93) per share for the quarter, down from their prior estimate of ($0.91). The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($3.72) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ Q3 2024 earnings at ($0.96) EPS, Q4 2024 earnings at ($1.25) EPS, FY2024 earnings at ($3.15) EPS, FY2025 earnings at ($3.89) EPS and FY2026 earnings at ($3.74) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.91. The company had revenue of $40.56 million during the quarter, compared to analyst estimates of $35.00 million. During the same period in the prior year, the firm earned ($1.07) earnings per share.

ZNTL has been the topic of several other reports. Stifel Nicolaus decreased their target price on shares of Zentalis Pharmaceuticals from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday. HC Wainwright decreased their price objective on shares of Zentalis Pharmaceuticals from $46.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Wedbush upped their target price on Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 28th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Zentalis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $37.14.

Zentalis Pharmaceuticals Stock Up 0.7 %

ZNTL stock opened at $12.52 on Friday. Zentalis Pharmaceuticals has a 52 week low of $9.56 and a 52 week high of $31.46. The business has a 50-day simple moving average of $13.65 and a 200 day simple moving average of $13.42. The company has a market cap of $889.05 million, a PE ratio of -2.76 and a beta of 1.82.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other news, CFO Melissa B. Epperly sold 2,573 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $11.44, for a total value of $29,435.12. Following the completion of the transaction, the chief financial officer now directly owns 451,449 shares in the company, valued at approximately $5,164,576.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Zentalis Pharmaceuticals news, insider Diana Hausman sold 3,356 shares of the company’s stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $12.62, for a total value of $42,352.72. Following the completion of the transaction, the insider now directly owns 373,876 shares in the company, valued at approximately $4,718,315.12. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Melissa B. Epperly sold 2,573 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $11.44, for a total transaction of $29,435.12. Following the transaction, the chief financial officer now directly owns 451,449 shares of the company’s stock, valued at approximately $5,164,576.56. The disclosure for this sale can be found here. Insiders have sold 7,102 shares of company stock worth $85,207 over the last quarter. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ZNTL. China Universal Asset Management Co. Ltd. lifted its holdings in Zentalis Pharmaceuticals by 132.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,809 shares of the company’s stock worth $36,000 after buying an additional 1,030 shares during the period. Quest Partners LLC bought a new stake in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $38,000. Tower Research Capital LLC TRC increased its position in Zentalis Pharmaceuticals by 252.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock valued at $55,000 after purchasing an additional 2,589 shares during the period. Exchange Traded Concepts LLC increased its position in Zentalis Pharmaceuticals by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company’s stock valued at $91,000 after purchasing an additional 1,519 shares during the period. Finally, OneAscent Financial Services LLC acquired a new position in shares of Zentalis Pharmaceuticals in the 4th quarter worth approximately $156,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.